Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Hematology

Uncovering the Root Cause: Why It Happened

At a Glance

Budd-Chiari Syndrome is usually caused by an underlying blood clotting disorder, most commonly Myeloproliferative Neoplasms (MPNs). Identifying the root cause, often through JAK2 mutation testing, is crucial for determining your long-term treatment strategy.

In most cases, Budd-Chiari Syndrome (BCS) is not a disease that starts on its own; rather, it is a complication of an underlying condition that makes your blood more likely to clot. Identifying this “root cause” is essential because it determines how you will be treated for the rest of your life.

The Blood Connection: Myeloproliferative Neoplasms

The most common cause of BCS is a group of blood disorders called Myeloproliferative Neoplasms (MPNs) [1][2]. In these conditions, the bone marrow produces too many red blood cells, white blood cells, or platelets.

The “Hidden” Clue: JAK2 Mutation

One of the most important tests you will receive is for the JAK2 V617F mutation [3]. This is a genetic change that acts like a “stuck on” switch for blood cell production.

  • Normal blood counts can be misleading: Many BCS patients have normal blood counts at the time of diagnosis because the liver and spleen are “trapping” the extra blood cells [4][5].
  • Occult MPN: Doctors call this “occult” or hidden MPN. Testing for the JAK2 mutation allows your team to find the underlying cause even when standard blood tests look perfect [4][6].

Other Systemic Causes

While MPNs are the leading cause, many other conditions can trigger the blood clots that lead to BCS:

  • Inherited Clotting Disorders: Genetic conditions like Factor V Leiden or Prothrombin gene mutations can make you naturally “hypercoagulable,” or prone to clotting [7][8].
  • Autoimmune Diseases: Conditions like Systemic Lupus Erythematosus (SLE) and Behçet’s Disease cause inflammation in the blood vessels, which can lead to blockages [9][10].
  • Antiphospholipid Syndrome (APS): An acquired autoimmune disorder where the body produces antibodies that mistakenly attack proteins in the blood, causing frequent clots [11][10].

Anatomical Subtypes: Where is the Blockage?

BCS can look different depending on exactly where the “plumbing” is blocked. Doctors generally distinguish between two main anatomical types:

Hepatic Vein Obstruction

This is the “classic” form of BCS, where the blockage occurs within the small veins inside the liver itself. This is the most common form seen in Western countries [12][13].

IVC Obstruction and MOVC

The Inferior Vena Cava (IVC) is the large “trunk line” vein that carries blood from the lower body and liver back to the heart.

  • Membranous Obstruction (MOVC): In some patients, particularly in populations within Asia and South Africa, the blockage is caused by a thin, web-like membrane stretching across the IVC [14][15].
  • A Simpler Fix: This subtype is unique because it can often be treated very effectively with balloon angioplasty [16][17]. A doctor inserts a small balloon, inflates it to break the membrane, and restores blood flow without the need for major surgery [16][18].

Understanding whether you have a vein-level clot or a membrane-level blockage is a key part of your diagnostic workup, as it directly changes your treatment options.

Return to the Budd-Chiari Syndrome Resource Guide.

Common questions in this guide

What is the most common cause of Budd-Chiari Syndrome?
The most common cause is a group of blood disorders called Myeloproliferative Neoplasms (MPNs). These conditions cause the bone marrow to produce too many blood cells, making your blood more prone to clotting.
Why is the JAK2 mutation test important if my blood counts are normal?
The JAK2 mutation test helps doctors identify hidden blood disorders that cause clotting. Many Budd-Chiari patients have normal blood counts because the liver and spleen trap the extra cells, making this genetic test essential for an accurate diagnosis.
What is membranous obstruction of the vena cava (MOVC)?
MOVC is a specific type of blockage where a thin, web-like membrane stretches across the inferior vena cava. Unlike other types of vein obstructions, MOVC can often be treated effectively with a minimally invasive balloon angioplasty.
Can autoimmune diseases cause Budd-Chiari Syndrome?
Yes, autoimmune conditions like Systemic Lupus Erythematosus (SLE), Behçet's Disease, and Antiphospholipid Syndrome can cause blood vessel inflammation or abnormal antibodies. This increases the risk of the blood clots that lead to the syndrome.
Why does it matter where the blockage is located?
The exact location of the blockage determines your treatment options. For example, a web-like membrane in the inferior vena cava might be fixed with a simple balloon procedure, whereas blockages inside the liver's smaller veins may require more complex treatments.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was I tested for the JAK2 V617F mutation, and what were the results?
  2. 2.If my blood counts appear normal right now, why is it still important to investigate for a 'hidden' or 'occult' blood disorder?
  3. 3.Does my imaging show a blockage in the hepatic veins, the inferior vena cava (IVC), or both?
  4. 4.Am I a candidate for a simple balloon dilation (angioplasty) rather than a more complex procedure like TIPS?
  5. 5.Have you screened me for systemic conditions like Behçet's disease or Antiphospholipid Syndrome (APS)?
  6. 6.Have we identified the root cause of my Budd-Chiari Syndrome?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.

    De Stefano V, Qi X, Betti S, Rossi E

    Thrombosis and haemostasis 2016; (115(2)):240-9 doi:10.1160/TH15-04-0326.

    PMID: 26333846
  2. 2

    A case of acute liver failure caused by Budd-Chiari syndrome salvaged by brain-dead donor liver transplantation.

    Kimura K, Osaki A, Hirata Y, et al.

    Clinical journal of gastroenterology 2024; (17(1)):84-92 doi:10.1007/s12328-023-01863-1.

    PMID: 37773425
  3. 3

    Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?

    Lamy M, Palazzo P, Agius P, et al.

    Cerebrovascular diseases (Basel, Switzerland) 2017; (44(3-4)):97-104 doi:10.1159/000471891.

    PMID: 28609766
  4. 4

    Detecting CALR Mutations in Splanchnic Vein Thrombosis: Who and How?

    Langabeer SE

    Journal of translational internal medicine 2018; (6(2)):55-57 doi:10.2478/jtim-2018-0015.

    PMID: 29984196
  5. 5

    Primary Myelofibrosis in the Prefibrotic Stage Presenting as Portal, Splenic, and Superior Mesenteric Vein Thrombosis: A Case Report and Review of the Literature.

    Dias E, Liberal R, Costa-Moreira P, et al.

    GE Portuguese journal of gastroenterology 2022; (29(2)):125-131 doi:10.1159/000514658.

    PMID: 35497670
  6. 6

    Acute upper gastrointestinal bleeding due to portal hypertension in a patient with primary myelofibrosis: A case report.

    Chen Y, Kong BB, Yin H, et al.

    World journal of clinical cases 2024; (12(15)):2621-2626 doi:10.12998/wjcc.v12.i15.2621.

    PMID: 38817215
  7. 7

    Budd-Chiari syndrome diagnosed with pregnancy in a patient with inherited thrombophilia.

    Elkhateb IT, Mousa A, Hashem A

    BMJ case reports 2021; (14(1)) doi:10.1136/bcr-2020-237761.

    PMID: 33462015
  8. 8

    The relationship between the levels and function of endothelial progenitor cells and factor V Leiden and protein C deficiency in patients with primary Budd-Chiari syndrome.

    Guan ZY, Yu CW, Song T, Gao Y

    European review for medical and pharmacological sciences 2018; (22(9)):2742-2750 doi:10.26355/eurrev_201805_14971.

    PMID: 29771426
  9. 9

    Budd- Chiari Syndrome as an Initial Manifestation of Systemic Lupus Erythematosus.

    Pandiaraja J, Sathyaseelan A

    Journal of clinical and diagnostic research : JCDR 2016; (10(4)):OD01-2 doi:10.7860/JCDR/2016/16623.7532.

    PMID: 27190864
  10. 10

    Budd-Chiari Syndrome as an Initial Presentation of Systemic Lupus Erythematosus Associated with Antiphospholipid Syndrome: A Case Report with Review of the Literature.

    Solela G, Daba M

    Open access rheumatology : research and reviews 2023; (15()):139-143 doi:10.2147/OARRR.S425535.

    PMID: 37605776
  11. 11

    Small hepatic veins Budd-Chiari syndrome and paroxysmal nocturnal hemoglobinuria - The association of two rare entities: a case report.

    Gioia S, De Santis E, Cerbelli B, et al.

    Pathologica 2020; (112(2)):102-104 doi:10.32074/1591-951X-4-20.

    PMID: 32760053
  12. 12

    Ultrasound Characteristics of Budd-Chiari Syndrome: A Multicenter Analysis.

    Daza J, Wiest I, Cui XW, et al.

    Digestive diseases (Basel, Switzerland) 2026; (44(2)):192-205 doi:10.1159/000549007.

    PMID: 41729746
  13. 13

    Review article: a multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome.

    Khan F, Armstrong MJ, Mehrzad H, et al.

    Alimentary pharmacology & therapeutics 2019; (49(7)):840-863 doi:10.1111/apt.15149.

    PMID: 30828850
  14. 14

    A single-center retrospective study: Clinical features of different types of Budd-Chiari syndrome in Chinese patients in the Hubei area.

    Li G, Huang Y, Tang S, et al.

    Vascular 2018; (26(1)):80-89 doi:10.1177/1708538117718638.

    PMID: 28738751
  15. 15

    Budd-Chiari Syndrome in Young Chinese: Clinical Characteristics, Etiology and Outcome of Recanalization from a Single Center.

    Zhou WJ, Cui YF, Zu MH, et al.

    Cardiovascular and interventional radiology 2016; (39(4)):557-65 doi:10.1007/s00270-016-1295-4.

    PMID: 26811088
  16. 16

    Comparison of Long-Term Outcomes of Endovascular Management for Membranous and Segmental Inferior Vena Cava Obstruction in Patients With Primary Budd-Chiari Syndrome.

    Huang Q, Shen B, Zhang Q, et al.

    Circulation. Cardiovascular interventions 2016; (9(3)):e003104.

    PMID: 26908849
  17. 17

    Long-term outcomes following percutaneous hepatic vein recanalization for Budd-Chiari syndrome.

    Tripathi D, Sunderraj L, Vemala V, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2017; (37(1)):111-120 doi:10.1111/liv.13180.

    PMID: 27254473
  18. 18

    Clinical outcomes of large diameter balloon angioplasty for Budd-Chiari syndrome with inferior vena cava involvement.

    Bi Y, Yi M, Han X, Ren J

    Journal of vascular surgery. Venous and lymphatic disorders 2021; (9(5)):1168-1177 doi:10.1016/j.jvsv.2021.01.006.

    PMID: 33529721

This page provides educational information about the underlying causes of Budd-Chiari Syndrome. It is not a substitute for professional medical advice; always consult your hematologist or hepatologist for a formal diagnosis.

Get notified when new evidence is published on Budd-Chiari syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.